Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase I/II Study Combining Sunitinib with Standard Ara-C/Daunorubicin Chemotherapy In Patients 60 Years or Older with FLT3 Mutated AML

Walter Fiedler, MD, Jürgen Krauter, MD, Katharina Götze, Helmut R. Salih, MD, Carsten Bokemeyer, MD, Daniela Spaeth, Konstanze Döhner, Hartmut Döhner, MD, Richard F. Schlenk, MD

Blood (2010) 116 (21): 3285.

https://doi.org/10.1182/blood.V116.21.3285.3285

Published: 2010

Journal Articles

Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Sabine Kayser, Konstanze Doehner, Juergen Krauter, Heinz A. Horst, Marie von Lilienfeld-Toal, Ulrich Germing, Katharina Goetze, Michael Pfreundschuh, Walter Fiedler, MD, Daniela Spaeth, Silja Groner, Brigitte Schlegelberger, Gudrun Goehring, Arnold Ganser, MD, Hartmut Doehner, Richard F. Schlenk

Blood (2009) 114 (22): 2621.

https://doi.org/10.1182/blood.V114.22.2621.2621

Published: 2009

Journal Articles

Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Blood (2009) 114 (22): 578.

https://doi.org/10.1182/blood.V114.22.578.578

Published: 2009

Journal Articles

Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1

Sabine Kayser, Richard F. Schlenk, Frank Breitenbücher, Martina Porebski, Kerstin Wittke, Juan Du, Silja Groner, Daniela Spaeth, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Thomas Fischer, Konstanze Döhner

Blood (2008) 112 (11): 2514.

https://doi.org/10.1182/blood.V112.11.2514.2514

Published: 2008

Journal Articles

RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG)

Verena I. Gaidzik, MD, Richard F. Schlenk, MD, Kerstin Wittke, Annegret Becker, Andreas Zimmermann, Brigitte Schlegelberger, MD, Arnold Ganser, MD, PhD, Daniela Spaeth, Hartmut Doehner, MD, Konstanze Doehner, MD

Blood (2008) 112 (11): 145.

https://doi.org/10.1182/blood.V112.11.145.145

Published: 2008

Journal Articles

Prognostic Role of Glutathione S-Transferase (GST) Polymorphisms in Acute Myeloid Leukemia.

Maria Teresa Voso, MD, Stefan Hohaus, MD, Francesco Guidi, PhD, Emiliano Fabiani, PhD, Francesco D’Alo’, MD, Silia Groener, MD, Daniela Spaeth, MD, Konstanze Dohner, MD, Giuseppe Leone, MD, Hartmut Dohner, MD, Richard F. Schlenk, MD

Blood (2007) 110 (11): 1446.

https://doi.org/10.1182/blood.V110.11.1446.1446

Published: 2007

NARROW

A Phase I/II Study Combining Sunitinib with Standard Ara-C/Daunorubicin Chemotherapy In Patients 60 Years or Older with FLT3 Mutated AML

Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1

RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG)

Prognostic Role of Glutathione S-Transferase (GST) Polymorphisms in Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

A Phase I/II Study Combining Sunitinib with Standard Ara-C/Daunorubicin Chemotherapy In Patients 60 Years or Older with FLT3 Mutated AML

Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.

Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1

RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG)

Prognostic Role of Glutathione S-Transferase (GST) Polymorphisms in Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only